We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Thrombocytopenia Prevalence in Acute Cancer-Associated Thrombosis Patients

By LabMedica International staff writers
Posted on 05 Oct 2022
Print article
Image: A blood film from a thrombocytopenic patient that is almost devoid of platelets (Photo courtesy of Professor Erhabor Osaro, FIBMS, PhD)
Image: A blood film from a thrombocytopenic patient that is almost devoid of platelets (Photo courtesy of Professor Erhabor Osaro, FIBMS, PhD)

Venous thromboembolism (VTE) is a common complication in patients with cancer, with thrombosis being the second leading cause of death among outpatients undergoing chemotherapy. Thrombocytopenia is also a common complication in patients with cancer, either due to the underlying malignancy or toxicity of cancer-directed therapy.

Due to the unique risk profile of cancer patients, management of cancer-associated thrombosis (CAT) requires special considerations as compared to VTE in non-cancer patients. Clinical decision-making in patients with cancer who develop both thrombosis and thrombocytopenia is challenging as thrombocytopenia increases the risk of bleeding without conferring protection against thrombosis.

Hematologists at the Beth Israel Deaconess Medical Center (Boston MA, USA) evaluated the prevalence of thrombocytopenia among patients with acute CAT. A retrospective cohort analysis of adult cancer patients was conducted between 2010 and 2021 with CAT (acute VTE within six months after new diagnosis of malignancy). VTE included acute deep vein thrombosis (DVT), pulmonary embolism (PE), abdominal or thoracic venous thrombosis, and cerebral sinus thrombosis (CST). The lowest platelet count within two weeks of (before or after) the index VTE event was identified to assess the frequency and grade of concurrent thrombocytopenia. The overall cohort was comprised of 47% females, with mean age 65.7 ± 12.8 years.

The scientists identified 3,635 patients with CAT (79.8% solid tumors, 17.8% hematologic malignancies, and 2.4% multiple concurrent cancer diagnoses). Thrombocytopenia (defined as platelet count <100,000/µL) occurred in 22% (95% CI 21%-24%) of patients with CAT with solid tumors diagnoses and 47% (95% CI 43%-51%) of patients with CAT and hematologic malignancies. Severe thrombocytopenia (platelet count <50,000/µL) occurred in 7% (95% CI 6%-8%) of patients with solid tumors and 30% (95% CI 27%-34%) of patients with hematologic malignancies.

The authors concluded that their study highlights the high co-prevalence of thrombocytopenia and CAT. Approximately 1 in 5 patients with solid tumors and 1 in 2 patients with hematologic malignancies with a diagnosis of VTE have concurrent thrombocytopenia. These point estimates serve to better define the scope of the problem and serve as justification for additional clinical trials addressing appropriate anticoagulation for acute CAT with thrombocytopenia. The study was published on September 28, 2022 in the journal Blood Advances.

Related Links:
Beth Israel Deaconess Medical Center 

Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
New
M. Tuberculosis Indirect Test
LIAISON QuantiFERON-TB Gold Plus
New
Silver Supplier
Urinalysis Dipstick Control
Dipper Urinalysis Dipstick Control
New
Albumin Urine Test
Micro-Albumin ELISA

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.